VMX-C001 + apixaban

VMX-C001 + apixaban is an **investigational combination therapy** involving VMX-C001, a recombinant variant of human coagulation factor X that is engineered to be insensitive to direct oral FXa inhibitors such as apixaban, paired with the small molecule anticoagulant apixaban. **VMX-C001 acts by bypassing and reversing the anticoagulant effect of FXa inhibitors** like apixaban, rapidly restoring coagulation in clinical scenarios such as serious bleeding or the need for urgent surgery. It is administered intravenously after oral dosing with apixaban, typically as part of a reversal or emergency protocol in subjects pre-treated with apixaban. VMX-C001 is under development by VarmX and has completed phase 1 trials in healthy subjects both alone and after apixaban exposure, demonstrating a good safety profile and a rapid, robust restoration of coagulation parameters as measured by thrombin generation, dilute prothrombin time, and dilute Russell’s viper venom time[1][2][4][5].